NCT06648525View on ClinicalTrials.gov

Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

October 31, 2024

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2028

Conditions
Intrahepatic Cholangiocarcinoma (Icc)
Interventions
DRUG

Adebrelimab

Adebrelimab, IV

DRUG

Irinotecan liposomes

Irinotecan liposomes, IV

DRUG

Lenvatinib

Lenvatinib, po

DRUG

5-Fluorouracil (5-FU)

5-Fluorouracil (5-FU), IV

DRUG

Calcium Folinate

Calcium folinate, IV

Trial Locations (1)

150081

Harbin Medical University, Harbin

All Listed Sponsors
lead

Harbin Medical University

OTHER

NCT06648525 - Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC | Biotech Hunter | Biotech Hunter